Nirmatrelvir / ritonavir (COVID-19, patients not requiring supplemental oxygen, with increased risk of progressing to severe COVID-19)

Subject:

• Active Substance: Nirmatrelvir / ritonavir
• Name: Paxlovid^®
• Therapeutic area: Coronavirus disease 2019 (COVID-19)
• Pharmaceutical company: Pfizer Pharma GmbH

Time table:

• Start: 01.07.2022
• Final decision by G-BA: 15.12.2022

Final decision:

• HInt for a considerable additional benefit